Originally broadcast March 11, 2014 - You can access the replay recording here (approximately 30 minutes).
This webcast provides attendees with an overview of the current and future landscape of how new pharmaceutical drugs are developed, from the perspective of how they are tested for safety. This perspective allows for a high but manageable level of medical and scientific detail, grounded by regulatory, social and resource drivers into detailed market forecasts, both niche and aggregate.
Participants will acquire insights and frameworks to better understand and evaluate opportunities across pharmaceuticals, drug development equipment and tools, bioinformatics, and services such as contract research organizations (CROs). (Note: Biologics are outside the scope of this topic.)
These insights will be most beneficial to product and service marketers, business development professionals, C-level decision-makers, investors, healthcare strategists, and information/big data technologists seeking a deeper understanding of specifically how the output of the genomic revolution is fueling exciting new solutions and markets.
These technologies are now enabling solutions to span wider segments of the healthcare landscape, from predictive toxicology in drug development, to biomarkers in clinical diagnostics. Along with great promise for healthcare, this is driving rapidly expanding global markets, forecast to grow from $5 Billion in 2012 to $10 Billion in 2017.
This informative event was presented by Robert Hunter, the analyst who authored BCC Research's recent report, "In Vitro Toxicity Testing: Technologies and Global Markets" (PHM017E).
- ClickToTweet, "http://bit.ly/predtox-webcast @BCCResearch #InVitro #InSilico Methods #PredictiveToxicology Help Develop #PrecisionMedicine with @bobghunter"